Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA loses global head of R&D

Senior reshuffle also sees departure of head of Merck Millipore
Merck Annalisa Jenkins

Merck KGaA has announced several changes in senior management positions across the group, including the departure of global head of R&D, Annalisa Jenkins.

The company did not provide a reason for the loss of Jenkins (pictured), although she recently took up the post of chair of the board of TransCelerate BioPharma.

Her role will be taken over on an interim basis by CEO of the company's Merck Serono division, Belén Garijo, until a permanent successor is found.

In addition, Udit Batra leaves his role as head of consumer health to become president and CEO of Merck Millipore, the company's biomanufacturing and life sciences research division.

Batra succeeds Robert Yates who led the integration of Millipore into Merck following the companies' decision to merge.

Replacing Batra as head of consumer health is Uta Kemmerich-Keil who is the current CEO of Merck's allergy business Allergopharma. In turn, Kemmerich-Keil is succeeded in her role by Marco Linari, the current commercial lead for the implementation of the operating model within Merck Millipore.

Karl-Ludwig Kley, chairman of the executive board, said: “Robert Yates and Annalisa Jenkins both played key roles in driving the change process in their respective areas of responsibility and I want to thank them personally for their contributions to Merck.”

27th March 2014

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics